Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Columns

Anatomic pathology selected abstracts

January 2025—The World Health Organization’s diagnostic criteria for malignant phyllodes tumor may miss a significant number of such tumors that have metastatic potential, according to a study conducted by the authors. Therefore, the authors proposed new refined diagnostic criteria for malignant phyllodes tumor (MPT) and conducted a study to validate the refined criteria. Their validation study included 136 borderline phyllodes tumors (BoPTs) and MPT cases that were not included in the initial study. The authors evaluated tumor classifications based on the refined criteria and World Health Organization (WHO) criteria. The revised criteria for MPT were either stromal overgrowth and one or more other features, such as marked stromal cellularity, marked stromal cytologic atypia, or at least 10 mitoses per 10 high-power fields (10 mitoses/10 HPF), or it was absence of stromal overgrowth and one or more other features, such as marked stromal cytologic atypia, at least 10 mitoses/10 HPF, or permeative border.

Pathology informatics selected abstracts

January 2025—Mismatch repair deficiency is a critical biomarker for identifying patients who may benefit from immunotherapy, and accurate classification is essential to making personalized treatment decisions. The authors conducted a study in which they presented a deep learning-based approach for classifying mismatch repair deficiency (MMR-D) in endometrial cancer using whole slide images of H&E-stained slides. They employed a multiresolution ensemble learning model in which they processed whole slide images at three magnifications—2.5×, 5×, and 10×—using a combination of the deep-learning architectures InceptionResNetV2, EfficientNetB2, and EfficientNetB3. These networks were trained on a data set of 1,168 whole slide images from 325 patients, with each whole slide image labeled by a pathologist for MMR-D or MMR proficiency (MMR-P) based on IHC results for the key MMR proteins MLH1, MSH2, MSH6, and PMS2. The authors addressed color variability in the H&E slides using a CycleGAN-based network for color normalization, ensuring consistency across the data set.

Molecular pathology selected abstracts

January 2025—Autism spectrum disorder is a neurodevelopmental disorder that has behavioral and social effects. Average patient age at diagnosis is approximately five years old. However, symptoms can appear within the first 12 months of life. The symptoms and severity of autism spectrum disorder (ASD) vary widely. They can include difficulty with verbal and nonverbal societal interaction, limited or repetitive behaviors, varying intellectual abilities, and emotional dysregulation.

Q&A column

January 2025
Q. In a CAP TODAY Q&A (published in August 2024), it was stated that a correlation between an automated and manual white blood cell count is not needed in clinical practice. Does this apply to digital imaging analyzers, such as those from CellaVision and Scopio, as well? If correlations between digital and manual differentials are required, what are your recommendations for acceptability? Read answer.

Q. When we write pathology reports, especially for prostatectomies, our diagnostic lines are often long, per CAP checklist requirements. In some cases, we retrim the surgical margins to evaluate the distal margins and note in the diagnostic line that margins will be studied further. When we report the margin status after retrimming, we are compelled to amend the report, leading to a large and somewhat confusing report because our long diagnostic lines are repeated; the only difference is the single line of the surgical margin. Do you have recommendations for creating an amended versus addendum report and addressing how the report can be more focused for clinicians and patients? Read answer.

Newsbytes

January 2025—NYU Langone Health, a New York-based multisite system with six inpatient facilities, is implementing digital pathology—some would say lightning quick considering its size. Having started the project in mid-October with six subspecialties, pathology services expects to fully implement the digital distribution of images systemwide by this spring. “What we’ve seen at other systems is a very slow transition that sometimes never gets accomplished to 100 percent,” says Joan Cangiarella, MD, vice chair of clinical operations, Department of Pathology, NYU Grossman School of Medicine. “Here we presented it as, ‘We are all going to go digital.’”

Put It on the Board

January 2025—The biochemical genetics and molecular technologies laboratories at Mayo Clinic in Rochester, Minn., reported in a recently published study that individuals with a TPMT*1/*8 diplotype displayed reduced thiopurine 6-mercaptopurine metabolism between that of normal metabolizers and intermediate metabolizers, suggesting that TPMT*8 is a reduced-function allele. That allele is common among individuals of African or African American ancestry (approximately 2.3 percent minor allele frequency), the authors write, but is not included in genotyping recommendations owing to its uncertain function.

From the President’s Desk

December 2024—Maybe you’ve had this experience: A patient calls, scared to death. They can’t reach their doctor and they can’t make sense of their pathology report. What they want to know is simple: What does it mean for my health? Now that pathology reports and lab results are going to many patients at the same time they’re released to ordering physicians, we pathologists have a new audience to keep in mind. It’s a major change in who’s reading our reports and how familiar they are with the terminology we use. (Let’s face it: Our reports read like Greek even to our fellow physicians. They must be downright mystifying to patients.)

Clinical pathology selected abstracts

December 2024—Excitement over the impact of artificial intelligence-based tools in different areas of health care has prompted position papers and research on the application of these new devices. One such tool is ChatGPT, which is publicly available and has demonstrated domain-specific knowledge in numerous areas, including medicine. The vast amount of data generated with current technologies, including digital pathology applications, and in subspecialty areas of pathology may lend itself to interpretation with artificial intelligence-based algorithms. But while AI-based applications can automate routine tasks and enhance diagnostic accuracy, their widespread use has been limited. Further AI research and validation of AI-based applications will increase adoption of such technology and, thereby, the overall efficiency and accuracy of the diagnostic process in pathology.

Anatomic pathology selected abstracts

December 2024—Recurrence of Crohn’s disease within one or two years of resection is common. The authors conducted a study in which they sought to identify histologic features in Crohn’s disease resections that may predict earlier recurrence (18 months or less) to potentially guide postoperative management. They performed a single-institution, retrospective database review of 41 patients who had first-time Crohn’s disease bowel resection specimens collected between October 2002 and December 2007. Patient demographics and Crohn’s disease course were documented. Slides were reviewed for the distribution and composition of inflammation, small bowel pyloric metaplasia, and the presence and characteristics of submucosal fibrosis and granulomas.

Molecular pathology selected abstracts

December 2024—Acute promyelocytic leukemia is generally characterized by presence of the PML::RARA fusion. However, a subset of cases with morphological, cytochemical, and immunophenotypic features of acute promyelocytic leukemia (APL) lack this canonical fusion gene and instead present with alternate fusions. These include RARA fusions with partners other than PML and fusions involving other retinoic acid receptor (RAR) genes, such as RARG. Leukemias with these variant fusions often resist all-trans retinoic acid (ATRA) therapy. Specifically, the ATRA sensitivity of RARA fusion genes varies based on its 5′ fusion partner. Interestingly, in some studies, the artificially induced variant RAR bipartite fusion genes responded well to ATRA.

MARKETPLACE

TRENDING